Ipca Laboratories Ltd's Q4FY25 Quarterly Results

Result Summary

• Ipca Laboratories Ltd reported a 9.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 32.6%.
• Its expenses for the quarter were down by 3.1% QoQ and up 29.6% YoY.
• The net profit decreased 99.5% QoQ and decreased 98.3% YoY.
• The earnings per share (EPS) of Ipca Laboratories Ltd stood at 2.4 during Q4FY25.

Financial Statments for Q4FY25

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Ipca Laboratories Ltd is a well-established pharmaceutical company involved in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs) globally. The company is known for its diverse product portfolio that includes pain management, cardiovascular, anti-malarial, and anti-infective drugs. In addition to its domestic presence, Ipca Labs has a significant international footprint, exporting to over 100 countries. As of the latest data available, the company has not announced any major recent developments.

Revenue

In Q4FY25, Ipca Laboratories Ltd reported a total income of ₹2051.93 crores. This reflects a decrease of 9.4% compared to the previous quarter (Q3FY25), where the total income was ₹2265.48 crores. However, on a year-over-year basis, there was a significant increase of 32.6% from Q4FY24, where the total income was ₹1548.02 crores. This indicates a strong annual growth in revenue despite a quarterly decline.

Profitability

For Q4FY25, the company recorded a Profit Before Tax (PBT) of ₹76.60 crores, which represents a substantial decline of 79.2% from the previous quarter (Q3FY25), where PBT was ₹367.92 crores. Compared to Q4FY24, PBT decreased by 40.8% from ₹129.44 crores. The Profit After Tax (PAT) for Q4FY25 was ₹1.33 crores, showing a dramatic decrease of 99.5% from Q3FY25, which was ₹276.36 crores, and a 98.3% decrease from the previous year (Q4FY24), where PAT stood at ₹78.14 crores. The Earnings Per Share (EPS) in Q4FY25 was ₹2.40, a decrease of 75.5% from Q3FY25 and a 20.0% decrease from Q4FY24.

Operating Metrics

In Q4FY25, Ipca Laboratories Ltd's total expenses were ₹1838.61 crores, representing a decrease of 3.1% from the previous quarter (Q3FY25), where the expenses were ₹1897.56 crores. Year-over-year, there was an increase of 29.6% from Q4FY24's expenses of ₹1418.58 crores. The tax expense for Q4FY25 was ₹73.69 crores, a decrease of 18.7% from the previous quarter's tax of ₹90.59 crores, but an increase of 52.3% from Q4FY24's tax figure of ₹48.37 crores. These figures highlight a reduction in quarter-over-quarter operating expenses, alongside an increase in expenses and tax on a year-over-year basis.